Cancer Research and Treatment

Discovery of a proliferation essential gene signature and actin‐like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple‐positive breast cancer

Xiaofen Li, Shiping Luo, Wenfen Fu, Mingyao Huang, Xiewei Huang, Shaohong Kang, Jie Zhang, Qingshui Wang, Chuangui Song

Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies

Silvana Di Palma, Panagiotis Koliou, Alex Simonovic, Daniela Costa, Catherine Faulkes, Brenda Kobutungi, Felicity Paterson, Jonathan David Horsnell, Farrokh Pakzad, Tracey Irvine, Polly Partlett, Elizabeth Clayton, Nadine Collins

International Journal of Molecular Sciences.2024; 25(5): 2616. CrossRef

iCluF: an unsupervised iterative cluster-fusion method for patient stratification using multiomics data

Sushil K Shakyawar, Balasrinivasa R Sajja, Jai Chand Patel, Chittibabu Guda, Marieke Kuijjer

Differences in Histological Subtypes of Invasive Lobular Breast Carcinoma According to Immunohistochemical Molecular Classification

Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović

Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study

Tobias Berg, Maj-Britt Jensen, Alan Celik, Maj-Lis Talman, Maria Anna Misiakou, Ann Søegaard Knoop, Finn Cilius Nielsen, Bent Ejlertsen, Maria Rossing

Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data

Kaiyuan Xing, Bo Zhang, Zixuan Wang, Yanru Zhang, Tengyue Chai, Jingkai Geng, Xuexue Qin, Xi Steven Chen, Xinxin Zhang, Chaohan Xu

Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes

Richard Lupat, Rashindrie Perera, Sherene Loi, Jason Li

Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer

Thérèse Dix-Peek, Boitumelo P. Phakathi, Eunice J. van den Berg, Caroline Dickens, Tanya N. Augustine, Herbert Cubasch, Alfred I. Neugut, Judith S. Jacobson, Maureen Joffe, Paul Ruff, Raquel A. B. Duarte

Breast Cancer Research and Treatment.2023; 199(1): 1. CrossRef

A Simple Method for Robust and Accurate Intrinsic Subtyping of Breast Cancer

Cancer Informatics.2023; 22: 117693512311598. CrossRef

XAI-MethylMarker: Explainable AI approach for biomarker discovery for breast cancer subtype classification using methylation data

Sheetal Rajpal, Ankit Rajpal, Arpita Saggar, Ashok K. Vaid, Virendra Kumar, Manoj Agarwal, Naveen Kumar

Expert Systems with Applications.2023; 225: 120130. CrossRef

XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes

Sheetal Rajpal, Ankit Rajpal, Manoj Agarwal, Virendra Kumar, Ajith Abraham, Divya Khanna, Naveen Kumar

Biomedical Signal Processing and Control.2023; 84: 104979. CrossRef

The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity

Vincenzo Salemme, Giorgia Centonze, Lidia Avalle, Dora Natalini, Alessio Piccolantonio, Pietro Arina, Alessandro Morellato, Ugo Ala, Daniela Taverna, Emilia Turco, Paola Defilippi

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Coralia Bueno Muiño, Miguel Martín, María del Monte-Millán, José Ángel García-Saénz, Sara López-Tarruella

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab

Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li

Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer

Xinyu Ren, Yu Song, Yanna zhang, Huanwen Wu, Longyun Chen, Junyi Pang, Liangrui Zhou, Songjie Shen, Zhiyong Liang

Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting

Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina

International Journal of Molecular Sciences.2022; 23(15): 8716. CrossRef

The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?

Felipe Andrés Cordero da Luz, Breno Jeha Araújo, Rogério Agenor de Araújo

Critical Reviews in Oncology/Hematology.2022; : 103781. CrossRef

Prognostic factors and molecular subtypes in young women with breast cancer

Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies

Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection

Bonil Koo, Dohoon Lee, Sangseon Lee, Inyoung Sung, Sun Kim, Sunho Lee

Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers

Clinical and Translational Oncology.2022; 25(4): 1024. CrossRef

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes

Marcela Carausu, Matthieu Carton, Véronique Diéras, Thierry Petit, Séverine Guiu, Anthony Gonçalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sébastien Frenel,

JAMA Network Open.2022; 5(12): e2247154. CrossRef

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review

Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang

PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study

Lin Wang, Qian Li, Vasily N. Aushev, Alfred I. Neugut, Regina M. Santella, Susan Teitelbaum, Jia Chen

Triphasic DeepBRCA-A Deep Learning-Based Framework for Identification of Biomarkers for Breast Cancer Stratification

Sheetal Rajpal, Manoj Agarwal, Virendra Kumar, Anamika Gupta, Naveen Kumar

Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level

Yan Zhang, Denan Zhang, Qingkang Meng, Ziqi Liu, Hongbo Xie, Lei Liu, Fei Xu, Xiujie Chen

A single-cell and spatially resolved atlas of human breast cancers

Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Lee Roden, Simon Junankar, Kate Harvey, Alma Andersson, Aatish Thennavan, Chenfei Wang, James R. Torpy, Nenad Bartonicek, Taopeng Wang, Ludvig Larsson, Dominik Kaczorowski, Neil I. Weisenfeld, Cedric R. Uytingco, Jen

Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method

Junmei Hao, Yan Lyu, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lyu, Wenfeng Zhang, Jianbo Zhang, Xunting Wang, Kuisheng Chen, Jiandi Zhang

Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma

Danhui Zhao, Xin Fu, Joseph Rohr, Yingmei Wang, Mingyang Li, Xiuming Zhang, Junhui Qin, Mengwei Xu, Chao Li, Guorui Sun, Zhe Wang, Shuangping Guo

Pathology - Research and Practice.2021; 228: 153677. CrossRef

Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets

Expert Review of Precision Medicine and Drug Development.2020; 5(1): 7. CrossRef

MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes

Elise Klæstad, Signe Opdahl, Monica Jernberg Engstrøm, Borgny Ytterhus, Elisabeth Wik, Anna Mary Bofin, Marit Valla

Breast Cancer Research and Treatment.2020; 180(1): 73. CrossRef

Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Liuwen Yu, Fangmeng Fu, Jing Li, Meng Huang, Bangwei Zeng, Yuxiang Lin, Qian Mei, Jinxing Lv, Chuan Wang

Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape

Seokhyun Yoon, Hye Sung Won, Keunsoo Kang, Kexin Qiu, Woong June Park, Yoon Ho Ko

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?

Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Zhu Li, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen

DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer

Lei Lei, Xiao-Jia Wang, Yin-Yuan Mo, Skye Hung-Chun Cheng, Yunyun Zhou

Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes

Baoai Han, He Zhang, Yuying Zhu, Xingxing Han, Zhiyong Wang, Zicong Gao, Yue Yuan, Ruinan Tian, Fei Zhang, Ruifang Niu

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib

Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park

Breast Cancer Research and Treatment.2020; 184(3): 743. CrossRef

Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification

Regine M Schoenherr, Uliana J Voytovich, Jeffrey R Whiteaker, Vijayakrishna K Gadi, Julie R Gralow, Amanda G Paulovich

A Topic Modeling Analysis of TCGA Breast and Lung Cancer Transcriptomic Data

Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease